Human Metabolome Technologies产品代理
Human Metabolome Technologies产品代理
HMT 可以通过使用 CE-MS 的代谢组分析技术识别 1,000 多种代谢物。此外，HMT 开发了独创的软件分析平台以及我们为实现代谢组分析而新开发的 CE-MS、LC-MS 和 MS/MS 等测量技术。此外，我们的目标是与庆应义塾大学高级生物科学研究所 (IAB) 合作，开发具有更高灵敏度和更高效率的更快代谢组分析技术。
HMT 的主要业务旨在为药物设计、诊断技术和食品生产中的代谢组学分析提供完整的解决方案，使用范围广泛的目标，包括人类和动物样本——我们是一家全方位服务的代谢组学供应商。
HMT 的代谢组学方法基于学术研究和科学领导的显着历史。联合创始人之一，IAB 所长 Masaru Tomita 教授，博士，计算生物学和代谢组学领域公认的领导者，在细胞代谢的计算机模拟方面进行了 10 多年的研究。富田教授与IAB教授Tomoyoshi Soga博士共同创立了HMT，他们建立了基于CE-MS的代谢组分析的前沿技术，是HMT核心技术的基础。阅读我们新任 CEO 桥目克仁先生的来信，请点击此处
HMT 成立于 2003 年 7 月，成功地采用基于收入的增长模式。该公司已获得新能源和工业技术开发组织 (NEDO) 的政府资助。 HMT 还建立了许多合作伙伴关系，包括 Agilent Technologies, Inc.、Mizkan Group Corporation、Ajinomoto, Co. Inc. 和 Mitsubishi Pharma Corporation。
Human Metabolome Technologies (HMT) is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions to drive drug discovery, diagnosis, and food production. Our research and development methodology are at the heart of an emerging field of metabolomics and systems biology.
HMT can identify more than 1,000 species of metabolites by the metabolome analysis technology using CE-MS. In addition, HMT developed an original software analysis platform along with the measuring technologies, such as CE-MS, LC-MS, and MS/MS, that we have newly developed for the realization of metabolome analysis. Furthermore, we aim to develop a faster metabolome analysis technology with higher sensitivity and higher efficiency in collaboration with the Institute for Advanced Biosciences (IAB), Keio University.
HMT’s primary business aims to provide complete solutions for metabolome analysis in drug design, diagnostic technology, and food production, using a wide range of targets including human and animal samples — We are a full-service metabolomic provider.
HMT’s metabolomics approach is based on a notable history of academic research and scientific leadership. One of the co-founders, Professor Masaru Tomita, Ph.D., Director of IAB, is a recognized leader in computational biology and metabolomics who has carried out research on computer simulations of cellular metabolism for over 10 years. Professor Tomita co-founded HMT with Tomoyoshi Soga, Ph.D., Professor at IAB, who established the cutting-edge technology of CE-MS based metabolome analysis, the basis of HMT’s core technology. Read a letter from our new CEO, Mr. Katsuhito Hashizume, Here
Founded in July 2003, HMT successfully operates on a revenue-based growth model. The company has been awarded government funding from the New Energy and Industrial Technology Development Organization (NEDO). HMT has also established a number of partnerships, including Agilent Technologies, Inc., Mizkan Group Corporation, Ajinomoto, Co. Inc., and Mitsubishi Pharma Corporation.
